Investigation on Professional Ethics of Pharmaceutical Industry in China

With the deepening of reform and the development of market economy, the state has promulgated a series of laws and regulations to purify the pharmaceutical market, and standardized the professional ethics of pharmaceutical enterprises and pharmaceutical entrepreneurs. However, we should be soberly aware that there are still gaps and deficiencies in the professional ethics construction of pharmaceutical enterprises and pharmaceutical entrepreneurs, and there is a trend of dilution and imbalance. Its main performance is as follows:

■ Not paying enough attention to professional ethics education

Medical professional ethics is the concrete embodiment of social moral norms and principles in medical professional activities. However, some pharmaceutical enterprises "pay more attention to economic benefits than professional ethics", think that paying attention to economic benefits is real and paying attention to professional ethics construction is empty, and there is a tendency of "being hard and soft", and they are too eager to pursue economic benefits and material factors, thus relaxing professional ethics education and ideological and political work. There is not enough research and discussion on the construction of professional ethics of pharmaceutical entrepreneurs under the condition of market economy, with more principles and less specific guidance, insufficient summary, exchange, popularization and implementation of professional ethics, and lack of effective publicity and supervision mechanism.

■ A few enterprises do not have a strong sense of quality, and some resort to deceit.

Some pharmaceutical enterprises ignore the supervision and control of drug quality, pay no attention to the basic conditions and infrastructure construction in drug production, and lack the necessary quality assurance system and system; Do not pay attention to civilized production, arbitrarily simplify or change the process operation procedures and standards, resulting in shoddy and irresponsible phenomenon; In the field of drug circulation, there are problems such as unlicensed operation, forced promotion of counterfeit and inferior drugs, price gouging, bribery and so on. Drug advertisements are exaggerated, arbitrarily exaggerated and confused with the truth.

■ Some enterprises overemphasize economic benefits and neglect social benefits.

Some pharmaceutical companies put economic benefits first, ignoring social benefits. In fact, the social and economic benefits of pharmaceutical companies are unified, and social benefits are the basis for generating economic benefits. Pharmaceutical enterprises should base their increasing economic benefits on improving social benefits.

■ Environmental awareness needs to be strengthened.

Although many pharmaceutical enterprises have established the treatment of "three wastes" discharge, their environmental awareness still needs to be strengthened. In order to pursue economic benefits, some enterprises do not hesitate to sacrifice the ecological environment and are unwilling to invest money, manpower and material resources to control pollution. The harmful substances in wastewater and waste gas discharged by some pharmaceutical enterprises seriously exceed the standard, which directly threatens the health of surrounding residents.

■ The problem drug recall has not formed a system.

No matter where defective drugs are found, it is the legal obligation of enterprises to recall them. However, there is no relevant regulation on drug recall in China's current drug supervision system, and "drug recall" belongs to the spontaneous and conscious behavior of enterprises.

The quality of drugs is related to people's lives. The pharmaceutical industry should be ahead of other industries in establishing and perfecting the recall system. Considering the safety of consumers, the healthy development of pharmaceutical economy and the fundamental interests of pharmaceutical production and operation enterprises, recalling problematic drugs should become the knowledge of pharmaceutical companies. However, some pharmaceutical companies are afraid to face up to these problems because they are worried that the public recall of problematic drugs will affect the company's product quality image, and they have adopted a concealed, laissez-faire and lucky attitude towards drugs found to have potential safety hazards. In fact, the courage to expose one's own ugliness and shortcomings just reflects the confidence of enterprises in the brand, and the humanized management and honest management of these enterprises will also win the respect of consumers.